Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm

References

• Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European group on Graves’ orbitopathy guidelines for the management of graves’ orbitopathy. Eur Thyroid J. 2016;5(1):9–26. doi:10.1159/00044382827099835
   PubMed Web of Science ®Google Scholar
• Douglas RS. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis. Eye (Lond). 2019;33(2):183–198. doi:10.1038/s41433-018-0321-y30575804
   PubMed Web of Science ®Google Scholar
• Smith TJ. New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor. F1000Res. 2018;7:134. doi:10.12688/f1000research29744034
   PubMedGoogle Scholar
• Smith TJ, Hegedus L. Graves’ disease. N Engl J Med. 2016;375(16):1552–1565. doi:10.1056/NEJMra151003027797318
   PubMed Web of Science ®Google Scholar
• Verity DH, Rose GE. Acute thyroid eye disease (TED): principles of medical and surgical management. Eye (Lond). 2013;27(3):308–319. doi:10.1038/eye.2012.28423412559
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT. Psychosocial morbidity of Graves’ orbitopathy. Clin Endocrinol (Oxf). 2005;63(4):395–402. doi:10.1111/j.1365-2265.2005.02352.x16181231
   PubMed Web of Science ®Google Scholar
• Park JJ, Sullivan TJ, Mortimer RH, Wagenaar M, Perry-Keene DA. Assessing quality of life in Australian patients with Graves’ ophthalmopathy. Br J Ophthalmol. 2004;88(1):75–78. doi:10.1136/bjo.88.1.7514693779
   PubMed Web of Science ®Google Scholar
• Minakaran N, Ezra DG. Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst Rev. 2013;5:CD009226.
   Google Scholar
• Hamed Azzam S, Kang S, Salvi M, Ezra DG. Tocilizumab for thyroid eye disease. Cochrane Database Syst Rev. 2018;11:CD012984.30480323
   PubMed Web of Science ®Google Scholar
• Douglas RS, Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol. 2011;22(5):385–390. doi:10.1097/ICU.0b013e328349944621730841
   PubMed Web of Science ®Google Scholar
• Bothun ED, Scheurer RA, Harrison AR, Lee MS. Update on thyroid eye disease and management. Clin Ophthalmol. 2009;3:543–551. doi:10.2147/opth.s522819898626
   PubMedGoogle Scholar
• Cyranska-Chyrek E, Olejarz M, Szczepanek-Parulska E, Stajgis P, Pioch A, Ruchala M. Severe unilateral orbitopathy in a patient with Hashimoto’s thyroiditis - a case report. BMC Ophthalmol. 2019;19(1):9. doi:10.1186/s12886-018-1018-530621642
   PubMed Web of Science ®Google Scholar
• Perros P, Neoh C, Dickinson J. Thyroid eye disease. Br Med J. 2009;338:b560. doi:10.1136/bmj.b90219270020
   PubMed Web of Science ®Google Scholar
• Mohyi M, Smith TJ. IGF1 receptor and thyroid-associated ophthalmopathy. J Mol Endocrinol. 2018;61(1):T29–T43. doi:10.1530/JME-17-027629273685
   PubMed Web of Science ®Google Scholar
• Sahli E, Gunduz K. Thyroid-associated ophthalmopathy. Turk J Ophthalmol. 2017;47(2):94–105. doi:10.4274/tjo.8068828405484
   PubMedGoogle Scholar
• Gillespie EF, Smith TJ, Douglas RS. Thyroid eye disease: towards an evidence base for treatment in the 21st century. Curr Neurol Neurosci Rep. 2012;12(3):318–324. doi:10.1007/s11910-012-0256-922354545
   PubMed Web of Science ®Google Scholar
• Khoo DH, Eng PH, Ho SC, et al. Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid. 2000;10(12):1093–1100. doi:10.1089/thy.2000.10.109311201855
   PubMed Web of Science ®Google Scholar
• Perros P, Hegedus L, Bartalena L, et al. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis. 2017;12(1):72. doi:10.1186/s13023-017-0625-128427469
   PubMed Web of Science ®Google Scholar
• Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994;92:477–588.7886878
   PubMedGoogle Scholar
• Perros P, Zarkovic M, Azzolini C, et al. PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group On Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol. 2015;99(11):1531–1535. doi:10.1136/bjophthalmol-2015-30673325953846
   PubMed Web of Science ®Google Scholar
• Stan MN, Bahn RS. Risk factors for development or deterioration of Graves’ ophthalmopathy. Thyroid. 2010;20(7):777–783. doi:10.1089/thy.2010.163420578901
   PubMed Web of Science ®Google Scholar
• Eckstein A, Quadbeck B, Mueller G, et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol. 2003;87(6):773–776. doi:10.1136/bjo.87.6.77312770979
   PubMed Web of Science ®Google Scholar
• Roos JCP, Paulpandian V, Murthy R. Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomy. Eye (Lond). 2019;33(2):212–217. doi:10.1038/s41433-018-0242-930401900
   PubMed Web of Science ®Google Scholar
• Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338(2):73–78. doi:10.1056/NEJM1998010833802019420337
   PubMed Web of Science ®Google Scholar
• Smith TJ. TSHR as a therapeutic target in Graves’ disease. Expert Opin Ther Targets. 2017;21(4):427–432. doi:10.1080/14728222.2017.128821528127991
   PubMed Web of Science ®Google Scholar
• Smith TJ, Janssen JA. Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy. Front Endocrinol (Lausanne). 2017;7:167. doi:10.3389/fendo.2016.0016728096798
   PubMed Web of Science ®Google Scholar
• Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol. 2008;181(6):4397–4405. doi:10.4049/jimmunol.181.6.439718768899
   PubMed Web of Science ®Google Scholar
• Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE. Thyrotropin receptor expression in graves’ orbital adipose/connective tissues: potential autoantigen in Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1998;83(3):998–1002. doi:10.1210/jcem.83.3.46769506762
   PubMed Web of Science ®Google Scholar
• Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity. 1993;16(4):251–257.7517705
   PubMed Web of Science ®Google Scholar
• Alsuhaibani AH, Nerad JA. Thyroid-associated orbitopathy. Semin Plast Surg. 2007;21(1):65–73. doi:10.1055/s-2007-96775120567660
   PubMedGoogle Scholar
• Smith TJ, Hegedus L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):291–302. doi:10.1016/j.beem.2011.10.00222632366
   PubMed Web of Science ®Google Scholar
• Krieger CC, Neumann S, Place RF, Marcus-Samuels B, Gershengorn MC. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves’ disease immunoglobins. J Clin Endocrinol Metab. 2015;100(3):1071–1077. doi:10.1210/jc.2014-356625485727
   PubMed Web of Science ®Google Scholar
• Douglas RS, Gianoukakis AG, Kamat S, Smith TJ. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves’ disease may carry functional consequences for disease pathogenesis. J Immunol. 2007;178(5):3281–3287. doi:10.4049/jimmunol.178.5.328117312178
   PubMed Web of Science ®Google Scholar
• Douglas RS, Naik V, Hwang CJ, et al. B cells from patients with Graves’ disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol. 2008;181(8):5768–5774. doi:10.4049/jimmunol.181.8.576818832736
   PubMed Web of Science ®Google Scholar
• Chen H, Mester T, Raychaudhuri N, et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014;99(9):E1635–E1640. doi:10.1210/jc.2014-158024878056
   PubMed Web of Science ®Google Scholar
• Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves’ disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol. 2002;168(2):942–950. doi:10.4049/jimmunol.168.2.94211777993
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hoa N. Immunoglobulins from patients with Graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004;89(10):5076–5080. doi:10.1210/jc.2004-071615472208
   PubMed Web of Science ®Google Scholar
• Li Q, Ye H, Ding Y, et al. Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases. PLoS One. 2017;12(5):e0176064. doi:10.1371/journal.pone.017606428472149
   PubMed Web of Science ®Google Scholar
• Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(3):284–290. doi:10.1016/s0002-9394(14)70276-48597271
   PubMed Web of Science ®Google Scholar
• Albert D, Miller J, Azar D, Blodi B. Albert & Jakobiec’s Principles & Practice of Ophthalmology. 3rd ed. Philadelphia, PA: Saunders; 2008.
   Google Scholar
• Savar LM, Menghani RM, Chong KK, Chokron Garneau H, Goldberg RA. Eyebrow tissue expansion: an underappreciated entity in thyroid-associated orbitopathy. Arch Ophthalmol. 2012;130(12):1566–1569. doi:10.1001/archophthalmol.2012.254323229698
   PubMedGoogle Scholar
• Kim BJ, Kazim M. Prominent premalar and cheek swelling: a sign of thyroid-associated orbitopathy. Ophthalmic Plast Reconstr Surg. 2006;22(6):457–460. doi:10.1097/01.iop.0000244972.03781.c617117102
   PubMed Web of Science ®Google Scholar
• Trobe JD, Glaser JS, Laflamme P. Dysthyroid optic neuropathy. clinical profile and rationale for management. Arch Ophthalmol. 1978;96(7):1199–1209. doi:10.1001/archopht.1978.03910060033007666628
   PubMedGoogle Scholar
• Hedges TR Jr, Scheie HG. Visual field defects in exophthalmos associated with thyroid disease. AMA Arch Ophthalmol. 1955;54(6):885–892.13268144
   PubMedGoogle Scholar
• Neigel JM, Rootman J, Belkin RI, et al. Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology. 1988;95(11):1515–1521. doi:10.1016/s0161-6420(88)32978-73211460
   PubMed Web of Science ®Google Scholar
• McKeag D, Lane C, Lazarus JH, et al. Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey. Br J Ophthalmol. 2007;91(4):455–458. doi:10.1136/bjo.2006.09460717035276
   PubMed Web of Science ®Google Scholar
• Rundle FF, Wilson CW. Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin Sci. 1945;5(3–4):177–194.21011937
   PubMed Web of Science ®Google Scholar
• Selva D, Chen C, King G. Late reactivation of thyroid orbitopathy. Clin Experiment Ophthalmol. 2004;32(1):46–50. doi:10.1046/j.1442-9071.2004.00756.x14746591
   PubMed Web of Science ®Google Scholar
• Patel P, Khandji J, Kazim M. Recurrent thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2015;31(6):445–448. doi:10.1097/IOP.000000000000037125621464
   PubMed Web of Science ®Google Scholar
• Baldeschi L, Lupetti A, Vu P, Wakelkamp IM, Prummel MF, Wiersinga WM. Reactivation of Graves’ orbitopathy after rehabilitative orbital decompression. Ophthalmology. 2007;114(7):1395–1402. doi:10.1016/j.ophtha.2006.10.03617320178
   PubMed Web of Science ®Google Scholar
• Shadpour JM, Menghani RM, Douglas RS, Goldberg RA, Tsirbas A. Reactivation of thyroid-associated orbitopathy after cataract surgery. Jpn J Ophthalmol. 2009;53(1):44–46. doi:10.1007/s10384-008-0607-x19184309
   PubMed Web of Science ®Google Scholar
• Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velazquez-Villoria A, Galofre JC. Graves’ ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015;2015:249125.26351570
   PubMed Web of Science ®Google Scholar
• Nicosia L, Reverberi C, Agolli L, et al. Orbital radiotherapy plus concomitant steroids in moderate-to-severe Graves’ ophthalmopathy: good results after long-term follow-up. Int J Endocrinol Metab. 2019;17(1):e84427.30881470
   PubMed Web of Science ®Google Scholar
• Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21(2):168–199. doi:10.1210/edrv.21.2.039310782363
   PubMed Web of Science ®Google Scholar
• Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97(11):3857–3865. doi:10.1210/jc.2012-275822962421
   PubMed Web of Science ®Google Scholar
• Kahaly G, Beyer J. Immunosuppressant therapy of thyroid eye disease. Klin Wochenschr. 1988;66(21):1049–1059. doi:10.1007/bf017119173070148
   PubMedGoogle Scholar
• Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology. 2001;108(9):1523–1534. doi:10.1016/s0161-6420(01)00632-711535445
   PubMed Web of Science ®Google Scholar
• Mourits MP, van Kempen-Harteveld ML, Garcia MB, Koppeschaar HP, Tick L, Terwee CB. Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study. Lancet (London, England). 2000;355(9214):1505–1509. doi:10.1016/S0140-6736(00)02165-6
   PubMed Web of Science ®Google Scholar
• Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2004;89(1):15–20. doi:10.1210/jc.2003-03080914715820
   PubMed Web of Science ®Google Scholar
• Bartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab. 1983;56(6):1139–1144. doi:10.1210/jcem-56-6-11396341388
   PubMed Web of Science ®Google Scholar
• Ng CM, Yuen HK, Choi KL, et al. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves’ ophthalmopathy: a preliminary study. Hong Kong Med J. 2005;11(5):322–330.16219950
   PubMedGoogle Scholar
• Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest. 1991;14(10):853–860. doi:10.1007/BF033479431802923
   PubMed Web of Science ®Google Scholar
• Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM. Randomized double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet (London, England). 1993;342(8877):949–954. doi:10.1016/0140-6736(93)92001-a
   PubMed Web of Science ®Google Scholar
• Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for Graves ophthalmopathy: a report by the American Academy of ophthalmology. Ophthalmology. 2008;115(2):398–409. doi:10.1016/j.ophtha.2007.10.02818082885
   PubMed Web of Science ®Google Scholar
• Bartalena L, Krassas GE, Wiersinga W, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97(12):4454–4463. doi:10.1210/jc.2012-238923038682
   PubMed Web of Science ®Google Scholar
• van Geest RJ, Sasim IV, Koppeschaar HP, et al. Methylprednisolone pulse therapy for patients with moderately severe Graves’ orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol. 2008;158(2):229–237. doi:10.1530/EJE-07-055818230831
   PubMed Web of Science ®Google Scholar
• Ebner R, Devoto MH, Weil D, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol. 2004;88(11):1380–1386. doi:10.1136/bjo.2004.04619315489477
   PubMed Web of Science ®Google Scholar
• Riedl M, Kuhn A, Kramer I, Kolbe E, Kahaly GJ. Prospective, systematically recorded mycophenolate safety data in Graves’ orbitopathy. J Endocrinol Invest. 2016;39(6):687–694. doi:10.1007/s40618-016-0441-926886940
   PubMed Web of Science ®Google Scholar
• Ye X, Bo X, Hu X, et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves’ orbitopathy. Clin Endocrinol (Oxf). 2017;86(2):247–255. doi:10.1111/cen.1317027484048
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Riedl M, Konig J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6(4):287–298. doi:10.1016/S2213-8587(18)30020-229396246
   PubMed Web of Science ®Google Scholar
• Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med. 1989;321(20):1353–1359. doi:10.1056/NEJM1989111632120022519530
   PubMed Web of Science ®Google Scholar
• Kahaly G, Schrezenmeir J, Krause U, et al. Ciclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986;16(5):415–422. doi:10.1111/j.1365-2362.1986.tb01016.x3100309
   PubMed Web of Science ®Google Scholar
• Antonelli A, Saracino A, Alberti B, et al. High-dose intravenous immunoglobulin treatment in Graves’ ophthalmopathy. Acta Endocrinol (Copenh). 1992;126(1):13–23. doi:10.1530/acta.0.12600131736548
   PubMedGoogle Scholar
• Kahaly G, Pitz S, Muller-Forell W, Hommel G. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves’ ophthalmopathy. Clin Exp Immunol. 1996;106(2):197–202. doi:10.1046/j.1365-2249.1996.d01-854.x8918563
   PubMed Web of Science ®Google Scholar
• Perros P, Weightman DR, Crombie AL, Kendall-Taylor P. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh). 1990;122(1):8–12. doi:10.1530/acta.0.12200082305608
   PubMedGoogle Scholar
• Kahaly G, Lieb W, Muller-Forell W, et al. Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study. Acta Endocrinol (Copenh). 1990;122(1):13–21. doi:10.1530/acta.0.12200132305603
   PubMedGoogle Scholar
• Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2004;89(12):5910–5915. doi:10.1210/jc.2004-069715579735
   PubMed Web of Science ®Google Scholar
• Wemeau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with Graves’ orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab. 2005;90(2):841–848. doi:10.1210/jc.2004-133415562016
   PubMed Web of Science ®Google Scholar
• Chang TC, Liao SL. Slow-release lanreotide in Graves’ ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest. 2006;29(5):413–422. doi:10.1007/BF0334412416794364
   PubMed Web of Science ®Google Scholar
• Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432–441. doi:10.1210/jc.2014-257225343233
   PubMed Web of Science ®Google Scholar
• Fichter N, Guthoff RF, Schittkowski MP. Orbital decompression in thyroid eye disease. ISRN Ophthalmol. 2012;2012:739236. doi:10.5402/2012/73923624558591
   PubMedGoogle Scholar
• Victores AJ, Takashima M. Thyroid eye disease: optic neuropathy and orbital decompression. Int Ophthalmol Clin. 2016;56(1):69–79. doi:10.1097/IIO.000000000000010126626933
   PubMedGoogle Scholar
• Rootman DB, Golan S, Pavlovich P, Rootman J. Postoperative changes in strabismus, ductions, exophthalmometry, and eyelid retraction after orbital decompression for thyroid orbitopathy. Ophthalmic Plast Reconstr Surg. 2017;33(4):289–293. doi:10.1097/IOP.000000000000075827487726
   PubMed Web of Science ®Google Scholar
• Yeatts RP. Quality of life in patients with Graves ophthalmopathy. Trans Am Ophthalmol Soc. 2005;103:368–411.17057811
   PubMedGoogle Scholar
• Jackson JL. Nonsurgical management of diplopia after orbital decompression surgery. Am Orthopt J. 2012;62:29–33.23002472
   PubMedGoogle Scholar
• Frueh BR, Musch DC, Garber FW. Lid retraction and levator aponeurosis defects in Graves’ eye disease. Ophthalmic Surg. 1986;17(4):216–220.3754942
   PubMedGoogle Scholar
• Ivekovic R, Novak-Laus K, Tedeschi-Reiner E, Masnec-Paskvalin S, Saric D, Mandic Z. Full-thickeness anterior blepharotomy and transpalpebral fat decompression in Graves’ orbitopathy. Coll Antropol. 2005;29(Suppl 1):33–36.
   PubMedGoogle Scholar
• Dixon R. The surgical management of thyroid-related upper eyelid retraction. Ophthalmology. 1982;89(1):52–57. doi:10.1016/s0161-6420(82)34861-77070774
   PubMed Web of Science ®Google Scholar
• Ribeiro SF, Shekhovtsova M, Duarte AF, Velasco Cruz AA. Graves lower eyelid retraction. Ophthalmic Plast Reconstr Surg. 2016;32(3):161–169. doi:10.1097/IOP.000000000000061326784547
   PubMed Web of Science ®Google Scholar
• Gardner TA, Kennerdell JS, Buerger GF. Treatment of dysthyroid lower lid retraction with autogenous tarsus transplants. Ophthalmic Plast Reconstr Surg. 1992;8(1):26–31.1554649
   PubMed Web of Science ®Google Scholar
• Oestreicher JH, Pang NK, Liao W. Treatment of lower eyelid retraction by retractor release and posterior lamellar grafting: an analysis of 659 eyelids in 400 patients. Ophthalmic Plast Reconstr Surg. 2008;24(3):207–212. doi:10.1097/IOP.0b013e318170684018520836
   PubMed Web of Science ®Google Scholar
• Genere N, Stan MN. Current and emerging treatment strategies for Graves’ orbitopathy. Drugs. 2019;79(2):109–124. doi:10.1007/s40265-018-1045-930659423
   PubMed Web of Science ®Google Scholar
• Planck T, Shahida B, Parikh H, et al. Smoking induces overexpression of immediate early genes in active Graves’ ophthalmopathy. Thyroid. 2014;24(10):1524–1532. doi:10.1089/thy.2014.015325135760
   PubMed Web of Science ®Google Scholar
• Nita M, Grzybowski A. Smoking and eye pathologies. a systemic review. part ii. retina diseases, uveitis, optic neuropathies, thyroid-associated orbitopathy. Curr Pharm Des. 2017;23(4):639–654. doi:10.2174/138161282366617011109572328078992
   PubMed Web of Science ®Google Scholar
• Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011;364(20):1920–1931. doi:10.1056/NEJMoa101298521591944
   PubMed Web of Science ®Google Scholar
• Burch HB, Lahiri S, Bahn RS, Barnes S. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves’ ophthalmopathy. Exp Eye Res. 1997;65(2):311–316. doi:10.1006/exer.1997.03539268599
   PubMed Web of Science ®Google Scholar
• Bouzas EA, Karadimas P, Mastorakos G, Koutras DA. Antioxidant agents in the treatment of Graves’ ophthalmopathy. Am J Ophthalmol. 2000;129(5):618–622. doi:10.1016/s0002-9394(00)00359-710844053
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet (London, England). 2008;371(9617):987–997. doi:10.1016/S0140-6736(08)60453-5
   PubMed Web of Science ®Google Scholar
• ACTEMRA^® (tocilizumab) [package insert] Injection, for Intravenous or Subcutaneous Use. Full Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2019.
   Google Scholar
• Slowik M, Urbaniak-Kujda D, Bohdanowicz-Pawlak A, et al. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves’ orbitopathy and correlate with disease activity. Endocr Res. 2012;37(2):89–95. doi:10.3109/07435800.2011.63562222489922
   PubMed Web of Science ®Google Scholar
• Russell DJ, Wagner LH, Seiff SR. Tocilizumab as a steroid sparing agent for the treatment of Graves’ orbitopathy. Am J Ophthalmol Case Rep. 2017;7:146–148. doi:10.1016/j.ajoc.2017.07.00129260102
   PubMedGoogle Scholar
• Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181–190. doi:10.1016/j.ajo.2018.07.03830081019
   PubMed Web of Science ®Google Scholar
• Ayabe R, Rootman DB, Hwang CJ, Ben-Artzi A, Goldberg R. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2014;30(5):415–419. doi:10.1097/IOP.000000000000021124978425
   PubMed Web of Science ®Google Scholar
• Durrani OM, Reuser TQ, Murray PI. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit. 2005;24(2):117–119. doi:10.1080/0167683059091256216191800
   PubMedGoogle Scholar
• Rajaii F, McCoy AN, Smith TJ. Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: from bench to bedside. Expert Rev Ophthalmol. 2014;9(3):227–234. doi:10.1586/17469899.2014.91796025544859
   PubMedGoogle Scholar
• RITUXAN^® (rituximab) [package insert] Injection, for Intravenous Use. Full Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2019.
   Google Scholar
• Salvi M, Vannucchi G, Curro N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422–431. doi:10.1210/jc.2014-301425494967
   PubMed Web of Science ®Google Scholar
• Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for Thyroid-Associated ophthalmopathy. N Engl J Med. 2017;376(18):1748–1761. doi:10.1056/NEJMoa161494928467880
   PubMed Web of Science ®Google Scholar
• Douglas RS, Sile S, Thompson EHZ, et al. Teprotumumab treatment effect on proptosis in patients with active thyroid eye disease: results from a phase 3, randomized, double-masked, placebo-controlled, parallel-group, multicenter study. Proceedings of the American Association of clinical endocrinologists. Endocr Pract. 2019;25(Supplement 1). doi:10.4158/EP-2018-0405
   Web of Science ®Google Scholar
• Bartley GB. Rundle and his curve. Arch Ophthalmol. 2011;129(3):356–358. doi:10.1001/archophthalmol.2011.2921402995
   PubMedGoogle Scholar
• Zang S, Ponto KA,Kahaly GJ. Clinical review:Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96:320–332.21239515
   PubMed Web of Science ®Google Scholar
• Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M, Pinchera A. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001;(86):3562–3567.11502779
   PubMed Web of Science ®Google Scholar